Links from this page to related variants, conditions, drugs and topics are not included for automated readers. Those connections are the Gene Knowledge Graph and are licensed as data: https://www.mygenelog.com/license

Sensitive

Type 2 diabetes

TCF7L2 · rs34872471

Strength of the evidence

3 / 4

Its strongest genetic-study result is p = 10−528, with 70 associations in the GWAS Catalog.

How this is scored

4: ClinVar disease-causing, reviewed by an expert panel or a guideline (3–4 stars). 3: ClinVar, several labs agreeing (2 stars), or a genetic study at p ≤ 10−50. 2: ClinVar from one lab (1 star), or p ≤ 10−20. 1: ClinVar submitted without criteria (0 stars), or genome-wide significance (p ≤ 5×10−8). The higher of the two counts. It says how solid the evidence is, not whether it matters for a particular person.

What the study found

Who was studied 746 African American cases, 2,825 African American controls, 743 East Asian ancestry cases, 3,992 East Asian ancestry controls, 7,111 European ancestry cases, 49,688 European ancestry controls, 1,147 Latino cases, 5,352 Latino controls; replicated in 12,171 European ancestry cases, 56,862 European ancestry controls.

The effect Each copy of the C allele carried 1.31 times the odds of Type 2 diabetes (95% confidence interval 1.26-1.35); p = 6 × 10−53.

How common The C allele had a frequency of about 28% in the people studied.

Where it sits Chromosome 10, band 10q25.2 — in an intron of TCF7L2.

How common each version is

CT
Korean KRGDB
C 2.9% · T 97.1%
Korean Korea4K
C 2.5% · T 97.5%
Korean Korea1K
C 2.8% · T 97.2%
Japanese ToMMo
C 4.7% · T 95.3%
Vietnamese
C 4.2% · T 95.8%
World gnomAD
C 29.1% · T 70.9%
World 1000 Genomes
C 24.2% · T 75.8%
World TOPMed
C 29.6% · T 70.4%

By ancestry gnomAD

East Asian
C 2.6% · T 97.4%
European (non-Finnish)
C 29.4% · T 70.6%
African / African American
C 34.9% · T 65.1%
South Asian
C 30.3% · T 69.7%
Admixed American (Latino)
C 27.2% · T 72.8%
Middle Eastern
C 41.5% · T 58.5%
Finnish
C 18.9% · T 81.1%
Ashkenazi Jewish
C 30.3% · T 69.7%

The share of all copies of this position that are each version. Source: the population studies published in dbSNP (US NCBI); each row names its study. The ancestry rows are gnomAD's own groups (via Ensembl), as the survey defines them, not races.

What each result means

C/C Two copies of the version the research linked to Type 2 diabetes. That is the strongest link of the three results. A link in a study is not a diagnosis.
C/T One copy of the version the research linked to Type 2 diabetes. That is a smaller link than two copies.
T/T No copy of the version the research linked to Type 2 diabetes. This is the starting point the study compared everyone against.
Source

In the news

2026-05-22 · Sinnott-Armstrong N, et al., Nature Communications 2026, PMID:42173832

Genetic variants affect diurnal glucose levels throughout the day

Circadian rhythms regulate glucose metabolism as well as sleep, but which genetic variants govern the timing of glucose had not been examined. Using the time of day each blood sample was taken, this study of about 420,000 UK Biobank participants — replicated in the Estonian Biobank, FinnGen, the VA Million Veteran Program and the MGB Biobank — shows that glucose levels are under diurnal genetic control. The two robust time-dependent signals are at MTNR1B, the melatonin receptor (rs10830963), and at CRY2, a core circadian clock gene (rs12419690). Sleep modulated glucose levels, the variants acted independently of sleep, they independently changed the risk of type 2 diabetes, and sleep medications including melatonin were associated with type 2 diabetes. Those two headline positions are not on this site yet; 21 other positions from the study are, among them rs560887 (G6PC2), rs34872471 (TCF7L2), rs3802177 (SLC30A8) and rs11708067 (ADCY5). PMID:42173832.

From our blog

A clock face whose hours are marked by a rising and falling line of blood sugar

Your Blood Sugar Keeps Time: The Clock Genes Behind the Midnight Snack

The same snack at noon and at midnight is not the same snack to your body. A 2026 study of nearly half a milli…

Quoting this page

Licensed CC BY-NC 4.0: free to read, share and adapt for non-commercial use, naming MyGeneLog™ and linking the exact page. Commercial use, including training or serving a commercial AI system, needs a licence — https://www.mygenelog.com/license

Type 2 diabetes (rs34872471). MyGeneLog™. https://www.mygenelog.com/variants/rs34872471

← See all variants